Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription Articles published in Nat Med Retrieve available abstracts of 18 articles: HTML format Text format

Single Articles

March 2019
1. NEWMAN S, Fan L, Pribnow A, Silkov A, et al
   Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.
   Nat Med. 2019 Mar 4. pii: 10.1038/s41591-019-0373.
   PubMed     Text format     Abstract available
   
   
   February 2019
2. HUANG AC, Orlowski RJ, Xu X, Mick R, et al
   A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
   Nat Med. 2019 Feb 25. pii: 10.1038/s41591-019-0357.
   PubMed     Text format     Abstract available
   
   
   December 2018
3. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
   Publisher Correction: Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
   Nat Med. 2018 Dec 18. pii: 10.1038/s41591-018-0325.
   PubMed     Text format     Abstract available
   
   
   
4. TRUCCO LD, Mundra PA, Hogan K, Garcia-Martinez P, et al
   Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
   Nat Med. 2018 Dec 3. pii: 10.1038/s41591-018-0265.
   PubMed     Text format     Abstract available
   
   
   November 2018
5. ROBERT C
   Is earlier better for melanoma checkpoint blockade?
   Nat Med. 2018;24:1645-1648.
   PubMed     Text format     Abstract available
   
   
   October 2018
6. CEREZO M, Guemiri R, Druillennec S, Girault I, et al
   Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
   Nat Med. 2018 Oct 29. pii: 10.1038/s41591-018-0217.
   PubMed     Text format     Abstract available
   
   
   
7. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
   Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
   Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0252.
   PubMed     Text format     Abstract available
   
   
   
8. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
   Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
   Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0251.
   PubMed     Text format     Abstract available
   
   
   
9. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
   Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
   Nat Med. 2018 Oct 17. pii: 10.1038/s41591-018-0247.
   PubMed     Text format     Abstract available
   
   
   
10. BLANK CU, Rozeman EA, Fanchi LF, Sikorska K, et al
    Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0198.
    PubMed     Text format     Abstract available
    
    
    
11. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 8. pii: 10.1038/s41591-018-0197.
    PubMed     Text format     Abstract available
    
    
    August 2018
12. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Aug 20. pii: 10.1038/s41591-018-0157.
    PubMed     Text format     Abstract available
    
    
    January 2018
13. BOSHUIZEN J, Koopman LA, Krijgsman O, Shahrabi A, et al
    Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
    Nat Med. 2018 Jan 15. pii: nm.4472. doi: 10.1038/nm.4472.
    PubMed     Text format     Abstract available
    
    
    October 2017
14. MURGAI M, Ju W, Eason M, Kline J, et al
    KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis.
    Nat Med. 2017;23:1176-1190.
    PubMed     Text format     Abstract available
    
    
    August 2017
15. XUE Y, Martelotto L, Baslan T, Vides A, et al
    An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Nat Med. 2017;23:929-937.
    PubMed     Text format     Abstract available
    
    
    July 2017
16. MAYORCA-GUILIANI AE, Madsen CD, Cox TR, Horton ER, et al
    ISDoT: in situ decellularization of tissues for high-resolution imaging and proteomic analysis of native extracellular matrix.
    Nat Med. 2017;23:890-898.
    PubMed     Text format     Abstract available
    
    
    December 2016
17. PEINADO H, Alec kovic M, Lavotshkin S, Matei I, et al
    Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
    Nat Med. 2016;22:1502.
    PubMed     Text format    
    
    
    October 2016
18. LINNEMANN C, van Buuren MM, Bies L, Verdegaal EM, et al
    Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
    Nat Med. 2016;22:1192.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: